Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.

Sirolimus has been granted Orphan Drug Designation for the treatment of sickle cell disease also in USA

RP announcement - read more

Orphan Drug Designation to sirolimus in Sickle Cell Disease

RP announcement - read more

The European Commission grants Orphan Drug Designation to Neupharma for the use of Teicoplanin in Cystic Fibrosis, a program developed in collaboration with Rare Partners

RP announcement - read more
Syndicate content